Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEX-DC®) in the Adjuvant Treatment of Gastric Cancer

Frank Gansauge and Bertram Poch

Center for Oncologic, Endocrine and Minimal-Invasive Surgery, Germany
LDG - Laboratories Dr. Gansauge - GmbH, Germany

^*Correspondance to: Frank Gansauge 

 PDF  Full Text Research Article | Open Access

Abstract:

Introduction: Even after surgical resection and multimodal treatment in gastric cancer the 5-year Disease Free Survival times (DFS) as well as Overall Survival rates (OS) are still below one third of the patients. Here we retrospectively analyzed the outcome of immunotherapy in the additional adjuvant treatment of gastric cancer with Long Antigen Exposition Dendritic Cell therapy (LANEXDC ®) in 16 patients who were treated at our institution (intent-to- treat-analysis).
Patients: Data were available of 16 patients. Dendritic Cells (LAEX-DC®) were produced according to a recently published protocol.
Results: Therapy was well tolerated and no serious side effects were observed. Five year DFS and OS were 62.5% and 67.5%. Interestingly, two of the patients developed recurrence of the disease more than 7 years following resection for gastric cancer.
Conclusion: We were able to show in a small cohort of patients that additional treatment with dendritic cells (LANEX-DC®) is highly effective and extends the DFS and OS in the adjuvant treatment of gastric cancer.

Keywords:

Gastric cancer; Dendritic cells; LANEX-DC®; Immunotherapy; Adjuvant

Cite the Article:

Gansauge F, Poch B. Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEX-DC®) in the Adjuvant Treatment of Gastric Cancer. Clin Oncol. 2022;7:1929..